SCHEMBL3533169

SCHEMBL3533169

CCN(CC#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)csc12)C(=O)OC(C)(C)C

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 17/20 0.63
FLT3 P36888 14/20 0.63
AURKA O14965 13/20 0.63
ABL1 P00519 13/20 0.63
LCK P06239 13/20 0.63
CSF1R P07333 13/20 0.63
MET P08581 13/20 0.63
FGFR1 P11362 13/20 0.63
FLT1 P17948 13/20 0.63
NEK2 P51955 13/20 0.63
ROCK1 Q13464 13/20 0.63
NTRK2 Q16620 13/20 0.63
KIT P10721 13/20 0.63
MAPK9 P45984 12/20 0.63
PLK4 O00444 11/20 0.63
MAPK13 O15264 11/20 0.63
INSR P06213 11/20 0.63
LYN P07948 11/20 0.63
FGFR3 P22607 11/20 0.63
RPS6KB1 P23443 11/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3530167 0.94 KDR (0.63) KDRFLT3AURKAABL1LCK
SCHEMBL3525281 0.91 KDR (0.67) KDRFLT3AURKAABL1LCK
SCHEMBL3532623 0.89 CSF1R (0.70) KDRFLT3AURKAABL1LCK
SCHEMBL3535176 0.89 KDR (0.69) KDRFLT3AURKAABL1LCK
SCHEMBL3530942 0.88 KDR (0.64) KDRFLT3AURKAABL1LCK
SCHEMBL3530698 0.87 CSF1R (0.67) KDRFLT3AURKAABL1LCK
SCHEMBL3614665 0.86 KDR (0.69) KDRFLT3AURKAABL1LCK
SCHEMBL3533925 0.86 KDR (0.67) KDRFLT3AURKAABL1LCK
SCHEMBL3533342 0.86 KDR (0.63) KDRFLT3AURKAABL1LCK
SCHEMBL3531752 0.86 KDR (0.72) KDRFLT3AURKAABL1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885FLT3 25/4885AURKA 207/4885
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885FLT3 25/4885AURKA 207/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885FLT3 25/4885AURKA 207/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885FLT3 25/4885AURKA 207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.